Skip to main content

Table 3 Subgroup analyses of paricalcitol compared with other VDRAs for target reduction of iPTH from baseline

From: Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials

Subgroup No.patients No.trials Relative Risk(95% CI) P Value I2(%) Test of Interaction, P
Total 696 5 1.01 (0.87,1.18) 0.85 31 Not applicable
Baseline iPTH level
  < 68.4 pmol/L 407 3 0.97 (0.78,1.20) 0.77 51 0.49
  > 68.4 pmol/L 289 2 1.09 (0.84,1.42) 0.51 13  
Types of dialysis
 Hemodialysis 670 4 1.03 (0.87,1.20) 0.76 41 0.44
 Peritoneal dialysis 26 1 0.78 (0.39,1.55) 0.47 31  
Routine of administration
 Oral 92 2 0.82 (0.61,1.11) 0.21 0 0.14
 Intravenous 604 3 1.07 (0.91,1.26) 0.42 38  
Sample size
 Small, n < 100 178 3 0.98 (0.75,1.28) 0.87 42 0.82
 Large, n > 100 518 2 1.02 (0.79,1.32) 0.88 60  
Risk of bias
 Low quality 92 2 0.82 (0.61,1.11) 0.21 0 0.14
 High quality 604 3 1.07 (0.91,1.26) 0.42 38